8-K: BioXcel Therapeutics Files for Chapter 11, Faces Nasdaq Delisting

BioXcel Therapeutics has filed for Chapter 11 bankruptcy protection and will be delisted from Nasdaq, while securing $77.25 million in debtor-in-possession financing.

Summary

• BioXcel Therapeutics, Inc. and its subsidiaries have filed for Chapter 11 bankruptcy protection.
• The company secured a $77.25 million debtor-in-possession (DIP) credit facility from affiliates of Oaktree Capital Management, L.P. and the Qatar Investment Authority.
• This DIP facility includes $19 million in new money loans and $58.25 million in roll-up loans, converting a portion of existing debt.
• The loans bear interest at 13.00% per annum, with default interest at 15.00%.
• The DIP facility matures on January 27, 2027, or earlier upon plan confirmation or asset sale.
• Nasdaq has determined to delist BioXcel Therapeutics' common stock, with trading suspension effective September 8, 2026.
• The common stock is expected to trade on the Pink Limited Market thereafter.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development due to the Chapter 11 bankruptcy filing and impending delisting from Nasdaq.

Positives

• Secured $77.25 million in debtor-in-possession financing to support operations during bankruptcy proceedings.
• The DIP facility includes $19 million in new capital, providing immediate liquidity.
• The company has a clear path to continue operating under Chapter 11 protection, subject to court approval and budget compliance.

Negatives

• The company and its subsidiaries have filed for Chapter 11 bankruptcy protection.
• The company's common stock will be delisted from The Nasdaq Capital Market.
• Trading suspension on Nasdaq is set for September 8, 2026.
• The stock is expected to trade on the Pink Limited Market, which is significantly less liquid and may depress the trading price.
• The DIP facility carries a high interest rate of 13.00% per annum, with a default rate of 15.00%.
• An exit fee of 4.0% of the aggregate principal amount of the loans is payable upon repayment.

Risks

• The company's ability to obtain timely court approval for motions filed in the bankruptcy cases.
• Compliance with the restrictions imposed by the DIP financing arrangements, including a minimum liquidity of $250,000.
• Maintaining relationships with suppliers, vendors, partners, employees, and regulatory authorities during the bankruptcy.
• The length of time the company will operate under Chapter 11 protection and continued availability of operating capital.
• Risks associated with third-party motions that could interfere with the company's ability to consummate a transaction.
• Increased administrative and legal costs related to the Chapter 11 process.
• Exposure to potential litigation related to the transaction and the bankruptcy process.
• The possibility that anticipated benefits of any transaction are not realized or that the transaction may be more expensive than anticipated.

Future Outlook

The company is operating under Chapter 11 protection and has secured financing to continue operations. The future outlook is highly dependent on the successful navigation of the bankruptcy process, court approvals, and potential restructuring or sale of assets. The delisting from Nasdaq and move to the Pink Sheets presents significant challenges for liquidity and investor confidence.

Management Comments

• Management is focused on obtaining court approval for necessary motions and continuing operations under Chapter 11.
• The company is working to maintain relationships with stakeholders during the bankruptcy proceedings.
• Management acknowledges the risks and uncertainties associated with the Chapter 11 process and forward-looking statements.

Industry Context

StockSavvy.ai notes that Chapter 11 filings and subsequent delistings are severe indicators of financial distress. Securing DIP financing is a critical step for continued operations, but the high interest rates and exit fees reflect the distressed nature of the financing. The move to the Pink Sheets signifies a significant downgrade in market perception and liquidity.

Legal Proceedings

• Voluntary petitions for relief under Chapter 11 of the Bankruptcy Code filed by BioXcel Therapeutics, Inc. and its subsidiaries in the United States Bankruptcy Court for the District of Delaware.

Stakeholder Impact

• Shareholders: Significant negative impact due to impending delisting from Nasdaq, expected trading on the less liquid Pink Sheets, and the inherent risks of bankruptcy proceedings which could lead to substantial dilution or loss of investment.
• Creditors: The Chapter 11 filing impacts the priority and recovery of existing creditors, with the DIP lenders having superpriority claims.
• Employees: Uncertainty regarding job security and compensation during the bankruptcy process.
• Suppliers and Vendors: Potential disruption in payment terms and ongoing business relationships due to the bankruptcy filing.

Next Steps

• Obtain final approval from the Court for the full DIP Facility.
• Continue operations under Chapter 11 protection.
• Manage administrative and legal costs associated with the Chapter 11 process.
• Potentially pursue a Chapter 11 plan of reorganization or a Section 363 asset sale.
• Transition trading of common stock to the Pink Limited Market.

Key Dates

Recommendation

The Chapter 11 filing, impending delisting from Nasdaq, and subsequent trading on the Pink Sheets represent severe financial distress and a significant increase in risk. The high cost of DIP financing and the uncertainty of the bankruptcy process make the stock a sell.

Keywords

Chapter 11, Bankruptcy, Debtor-in-Possession Financing, DIP Credit Agreement, Nasdaq Delisting, Pink Sheets, Oaktree Capital Management, Qatar Investment Authority